KEY TAKEAWAYS
- The STELLAR phase II trial aimed to evaluate the effectiveness of a predefined multidisciplinary approach to prevent and manage mild-moderate skin AEs associated with TTFields therapy in pts with pleural mesothelioma.
- Pts received TTFields therapy in combination with chemotherapy, and AEs were managed using a center-specific protocol.
- The study found this approach can help prevent and manage skin AEs from TTFields therapy.
Tumor Treating Fields (TTFields) therapy is a non-invasive treatment for glioblastoma and pleural mesothelioma that uses electric fields to disrupt cancer cells. The most common side effect is mild-to-moderate skin reactions, which can be managed properly.
Researchers aimed to evaluate the effectiveness of a predefined multidisciplinary approach to prevent and manage mild-moderate skin adverse events (AEs) associated with TTFields therapy in patients(pts) with pleural mesothelioma.
Pts received TTFields therapy (150 kHz, 18 h/day) alongside pemetrexed (500 mg/m2) and platinum-based chemotherapy (75 mg/m2). The study was multicenter, single-arm, and non-randomized. TTFields therapy AEs were addressed using a center-specific protocol.
About 23 pts were treated using the skin AE prevention protocol. All were included in the safety analysis, 15 pts (65%) reported mild-moderate skin AEs (n = 12 [52%] medical device site reaction [skin AE], n = 1 [4%] had a mild-moderate rash, rash erythematous and skin irritation). This incidence was slightly lower than the overall STELLAR study population (68%), 2 pts (9%) in the single center experienced severe medical device site reactions, aligning with the incidence in the STELLAR study population.
The study found this approach can help prevent and manage skin AEs from TTFields therapy. Guidelines for skin care should be followed to optimize patient outcomes.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e20542
Clinical Trial: https://clinicaltrials.gov/study/NCT02397928
Federica Grosso, Sara Delfanti, Giulia Gallizzi, Francesca Marengo, Iacopo Megna, Carlotta Bertolina, and Giovanni Luca Ceresoli. DOI: 10.1200/JCO.2023.41.16_suppl.e20542 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e20542-e20542.
